within Pharmacolibrary.Drugs.ATC.A;

model A16AX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.11,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trientine is a chelating agent used primarily for the treatment of Wilson’s disease, a rare genetic disorder that leads to copper accumulation in tissues. It is an alternative therapy for patients who are intolerant to penicillamine. Trientine binds copper and promotes its urinary excretion. It is an approved medication and is currently used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult healthy volunteers and patients with Wilson's disease; values are based on data compiled from literature for oral administration in typical clinical doses.</p><h4>References</h4><ol><li><p>Pfeiffenberger, J, et al., &amp; Weiss, KH (2018). The steady state pharmacokinetics of trientine in Wilson disease patients. <i>European journal of clinical pharmacology</i> 74(6) 731–736. DOI:<a href=&quot;https://doi.org/10.1007/s00228-018-2424-6&quot;>10.1007/s00228-018-2424-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29417175/&quot;>https://pubmed.ncbi.nlm.nih.gov/29417175</a></p></li><li><p>Weiss, KH, et al., &amp; Kamlin, COF (2021). Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 46(5) 665–675. DOI:<a href=&quot;https://doi.org/10.1007/s13318-021-00704-1&quot;>10.1007/s13318-021-00704-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34357516/&quot;>https://pubmed.ncbi.nlm.nih.gov/34357516</a></p></li><li><p>Huang, YF, et al., &amp; Chou, CY (2019). A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. <i>Frontiers in oncology</i> 9 437–None. DOI:<a href=&quot;https://doi.org/10.3389/fonc.2019.00437&quot;>10.3389/fonc.2019.00437</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31179244/&quot;>https://pubmed.ncbi.nlm.nih.gov/31179244</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX12;
